Maeva Dufies

Monaco, Monaco

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

All screens lead to polo-like kinase 1: A central node in cancer therapeutics and resistance.

All screens lead to polo-like kinase 1: A central node in cancer therapeutics and resistance.

Journal: Pharmacological research

Published: February 04, 2026

STK17A (DRAK1) at the crossroads of apoptosis, immunity, and cancer: Emerging roles and therapeutic opportunities.

STK17A (DRAK1) at the crossroads of apoptosis, immunity, and cancer: Emerging roles and therapeutic opportunities.

Journal: Theranostics

Published: December 13, 2025

Connective tissue growth factor contributes to resistance to anti-angiogenic therapies in renal cancer.

Connective tissue growth factor contributes to resistance to anti-angiogenic therapies in renal cancer.

Journal: Theranostics

Published: September 16, 2025

Comparative impact of proton versus photon irradiation on triple-negative breast cancer: Role of VEGFC in tumour aggressiveness.

Comparative impact of proton versus photon irradiation on triple-negative breast cancer: Role of VEGFC in tumour aggressiveness.

Journal: Clinical and translational medicine

Published: November 22, 2024

Aqueous humor mediator levels as biomarkers of anti-VEGF response in age-related macular degeneration.

Aqueous humor mediator levels as biomarkers of anti-VEGF response in age-related macular degeneration.

Journal: Cytokine

Published: October 10, 2024

Disrupting USP39 deubiquitinase function impairs the survival and migration of multiple myeloma cells through ZEB1 degradation.

Disrupting USP39 deubiquitinase function impairs the survival and migration of multiple myeloma cells through ZEB1 degradation.

Journal: Journal of experimental & clinical cancer research : CR

Published: July 12, 2024

A Potent Solution for Tumor Growth and Angiogenesis Suppression via an ELR+CXCL-CXCR1/2 Pathway Inhibitor.

A Potent Solution for Tumor Growth and Angiogenesis Suppression via an ELR+CXCL-CXCR1/2 Pathway Inhibitor.

Journal: ACS medicinal chemistry letters

Published: January 31, 2024

Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001.

Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001.

Journal: Journal of experimental & clinical cancer research : CR

Published: November 13, 2023

New Phenylspirodrimanes from the Sponge-Associated Fungus Stachybotrys chartarum MUT 3308.

New Phenylspirodrimanes from the Sponge-Associated Fungus Stachybotrys chartarum MUT 3308.

Journal: Marine drugs

Published: January 29, 2023

A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma.

A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma.

Journal: Molecular oncology

Published: December 04, 2022

Targeting of the ELR+CXCL/CXCR1/2 Pathway Is a Relevant Strategy for the Treatment of Paediatric Medulloblastomas.

Targeting of the ELR+CXCL/CXCR1/2 Pathway Is a Relevant Strategy for the Treatment of Paediatric Medulloblastomas.

Journal: Cells

Published: October 12, 2022

Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma.

Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma.

Journal: Cell reports. Medicine

Published: June 30, 2021

Showing 1-12 of 55

Last Updated: 09/26/2026